MORE than 5,000 Australians every year who suffer from relapsing-remitting multiple sclerosis will benefit from affordable access to a major new life-changing medicine from this month with the announcement of the Pharmaceutical Benefits Scheme addition of ocrelizumab.
The Minister for Health Greg Hunt said Ocrevus (ocrelizumab by Roche Products) "decreases the number of flare-ups and slows the worsening of RRMS".
Instead of $35,100 pa this drug will be available for a maximum of $39.50 per script - health.gov.au.
For the full list of PBS listings and changes see pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Feb 18
